Literature DB >> 23368747

Reduced medium-term mortality following primary total hip and knee arthroplasty with an enhanced recovery program. A study of 4,500 consecutive procedures.

Terence Savaridas1, Ignacio Serrano-Pedraza, Sameer K Khan, Kate Martin, Ajay Malviya, Mike R Reed.   

Abstract

BACKGROUND AND
PURPOSE: Our unit started to use routine multimodal techniques to enhance recovery for hip and knee arthroplasty in 2008. We have previously reported earlier discharge, a trend toward a reduction in complications, and a statistically significant reduction in mortality up to 90 days after surgery. In this study, we evaluated the same cohort to determine whether survival benefits were maintained at 2 years. PATIENTS AND METHODS: We prospectively evaluated 4,500 unselected consecutive total hip and knee replacements. The first 3,000 underwent a traditional protocol (TRAD) and the later 1,500 underwent an enhanced recovery protocol (ER). Mortality data were collected from the Office of National Statistics (UK).
RESULTS: There was a difference in death rate at 2 years (TRAD vs. ER: 3.8% vs. 2.7%; p = 0.05). Survival probability up to 3.7 years post surgery was significantly better in patients who underwent an ER protocol.
INTERPRETATION: This large prospective case series of unselected consecutive patients showed a reduction in mortality rate at 2 years following elective lower-limb hip and knee arthroplasty following the introduction of a multimodal enhanced recovery protocol. This survival benefit supports the routine use of an enhanced recovery program for hip and knee arthroplasty.

Entities:  

Mesh:

Year:  2013        PMID: 23368747      PMCID: PMC3584601          DOI: 10.3109/17453674.2013.771298

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


Randomized controlled trials (Reilly et al. 2005, Andersen et al. 2007, Larsen et al. 2008) and clinical series (McDonald et al. 2011) have shown a significant reduction in length of stay in hospital following lower limb arthroplasty with the implementation of enhanced recovery (ER) programs. ER programs are based on the use of multimodal strategies to improve analgesia while at the same time reducing the surgical stress response and organ dysfunction (including nausea, vomiting, and ileus), thus facilitating earlier patient mobilization and return to oral fluids and diet (Kehlet and Wilmore 2008). This enables commencement of functional rehabilitation within the first few hours after surgery (Husted et al. 2011, McDonald et al. 2011). The use of multimodal strategies has resulted in faster patient rehabilitation and improved satisfaction (Kehlet and Wilmore 2002). Our hospital introduced an ER program for hip and knee arthroplasty in May 2008. We have previously published our findings of statistically significant reductions in length of hospital stay and mortality within 30 days and 90 days of surgery by the use of an ER program compared to our traditional protocol (Malviya et al. 2011). The 90-day mortality of 0.2% in our unit after implementation of an ER program is similar to that previously reported in units with established ER programs (Husted et al. 2010). Very few results have been published regarding comparison of longer-term mortality after implementation of ER programs in comparison to controls from a cohort of patients whereby multimodal strategies were not used in the perioperative period. A recent study from the United Kingdom found no difference in mortality 1 year after primary total knee arthroplasty following implementation of an ER program in comparison with a historical cohort (McDonald et al. 2011). We now report on mortality more than 3 years postoperatively following the introduction of an ER program, in comparison to the results of our traditional protocol.

Patients and methods

Data from 4,500 unselected consecutive primary hip and knee replacements were analyzed. 3,000 procedures were performed between March 2, 2004 and May 1, 2008, immediately prior to implementation of the enhanced recovery program (the traditional (TRAD) group); 1,500 procedures were performed with an enhanced recovery program (the enhanced recovery (ER) group) between May 2, 2008 and November 3, 2009. The treating surgeons’ indications for hip and knee arthroplasty remained unchanged. The protocols that were followed in both groups have been published previously (Malviya et al. 2011). The patients were from a consecutive unselected series. Comparison of patient demographics before surgery in the 2 groups—as previously published (Malviya et al. 2011)—are presented in Table 1. Chi-squared test was used to compare proportions (Fleiss et al. 2003).
Table 1.

Comparison of patient demographics preoperatively in the 2 groups

TRAD (n = 3,000) ER (n = 1,500) p-value a
Mean age, years6968
THR1368630
TKR1632870
Sex (M : F)1482 : 1518711 : 7890.2
Co-morbidities, n (%)
 Hypertension921 (31)673 (45)< 0.001
 Atrial fibrillation143 (5)84 (6)0.3
 Ischemic heart disease211 (7)113 (8)0.6
 Diabetes mellitus
 insulin-dependent20 (0.7)18 (1)0.09
 non-insulin-dependent205 (7)150 (10)< 0.001
 Chronic obstructive
 pulmonary disease85 (3)67 (4)0.006
 Alzheimer’s disease6 (0.2)5 (0.3)0.6

Chi-squared test with continuity correction.

Comparison of patient demographics preoperatively in the 2 groups Chi-squared test with continuity correction. Mortality data were obtained from the Office of National Statistics (ONS). In England, deaths must be registered within 5 days. Burials and cremations cannot be conducted without this registration documentation. These deaths are recorded by the ONS and are added to the patient’s health service record. The cause of death for patients that died within our NHS trust was obtained from inspection of hospital case notes, and was cross-referenced with ONS data.

Statistics

The death rates and cause-of-death data presented for postoperative times up to 2 years include the actual data for all 4,500 patients. There was a greater proportion of patients in the TRAD group with longer follow-up data. The death rates beyond 2 years are therefore only reported using Kaplan-Meier (K-M) survival analysis. K-M survival curves with Greenwood’s 95% confidence interval (CI) were used to assess and compare the survival probability between groups (TRAD and ER). The log-rank test was used to test for any statistically significant difference between the 2 K-M curves (Bland and Altman 2004). Furthermore, the log-rank test was used to determine whether there were any differences in survival, between hip and knee arthroplasty, within each group.

Results

After initiation of the ER program, the mortality rate following primary hip and knee arthroplasty was reduced (p = 0.05) at 2 years (Table 2). With time (up to 3.7 years), the difference in mortality appeared to increase as the K-M survival curves diverged (χ2log-rank = 16, p < 0.001) (Figure 1).
Table 2.

Comparison of mortality rates in the two groups

TRAD (n = 3,000) ER (n = 1,500) p-value (chi-squared test)
Dead by 1 year63 (2.1%)19 (1.3%)0.05
Dead by 2 years114 (3.8%)40 (2.7%)0.05
Figure 1.

Kaplan-Meier (K-M) survival curves for both groups ± 95% Greenwood confidence interval (dotted lines). Note that the two K-M survival curves fall outwith the ± 95% Greenwood confidence intervals. The level of significance is 0.05.

Comparison of mortality rates in the two groups Kaplan-Meier (K-M) survival curves for both groups ± 95% Greenwood confidence interval (dotted lines). Note that the two K-M survival curves fall outwith the ± 95% Greenwood confidence intervals. The level of significance is 0.05. In the ER group, with a sample size that was half that of the TRAD group, it could be expected that the number of deaths at different intervals postoperatively would be half that of the TRAD group. With time, the difference in mortality appeared to increase; there were 12 fewer deaths than expected in the ER group at 1 year and this increased to 17 fewer deaths at 2 years in the ER cohort of 1,500 patients. Although fewer patients in the ER group had 3.7-year follow-up, the projected difference at that point was 5% (75 patients). From case notes and ONS data, we were unable to ascertain the cause of death of 9 patients in the TRAD group and of 7 patients in the ER group. The cause of death data (Figure 2) show that at 2 years after surgery, a greater proportion of deaths were related to malignant disease in the TRAD group than in the ER group. Almost half of the patients who died due to malignant disease within 2 years in the ER group (4 of 9) had a known diagnosis of cancer prior to arthroplasty surgery. In the TRAD group, approximately one third of deaths from malignant disease (14 of 36) were in patients who were known to have developed cancer before joint replacement surgery. When K-M survival probability graphs were plotted for both groups after exclusion of all deaths that had been due to malignant disease, there were divergent curves (χ2log-rank = 11, p < 0.001), indicating that a survival benefit remained up to 3.7 years after surgery for patients who underwent an ER protocol.
Figure 2.

Cause of death for patients who died up to 2 years post surgery, reported as a rate per 1,000 procedures.

Cause of death for patients who died up to 2 years post surgery, reported as a rate per 1,000 procedures.

Discussion

The ER program is intended to facilitate an early return to function by minimizing stress-induced organ dysfunction after major surgery and its associated morbidity (Kehlet and Wilmore 2002). Implementation of the ER program appeared to have a positive effect on reducing patient mortality following lower limb arthroplasty; this persisted up to 3.7 years postoperatively. The reason for this prolonged and apparently increasing beneficial effect is not known, but it may relate to the reduced stress response, shorter hospital stay, and improved pain control in the ER program group (Kehlet and Wilmore 2002, McDonald et al. 2011). With the initiation of an ER program in our unit, there was a statistically significant decrease in the postoperative transfusion rate. In contrast, in the TRAD group, there tended to be a greater range of complications—which included return to theater, hospital re-admission, stroke, myocardial infarction, acute renal failure, and thromboembolic events—within the first 2 postoperative months (Malviya et al. 2011). A recent review of prospectively collected multicenter data from over 100,000 patients who had undergone surgical procedures (a proportion of whom had THRs) showed that the occurrence of a postoperative complication within the first 30 days reduced median patient survival at 5 years, independently of patient risk preoperatively (Khuri et al. 2005). The authors suggested that the presence of an inflammatory response related to the postoperative complication may have been a contributory factor to the reduced longer-term survival. Likewise, the reduced 30-day postoperative complication incidence in the ER group in our study may explain the improved longer-term survival. In addition, the stated aim of ER programs—to use multimodal strategies to reduce the surgery-mediated inflammatory stress response (Kehlet and Wilmore 2008)—may in itself contribute to improved longer-term survival. There has been an increase in detection rates, possibly related to better patient awareness, and there have also been improvements in treatment modalities for the most common malignant diseases in the United Kingdom, namely prostate cancer, breast cancer, colorectal cancer, and lung cancer. The benefits gained from these are evident from the steady increase in 1-year survival rates after diagnosis of a malignant disease over the last 5 years (CancerResearchUK.org, accessed Aug 8. 2012). This may partly explain the higher proportion of deaths related to malignant disease in the TRAD group, which was the historical cohort. Furthermore, there is some evidence in the literature to suggest an increase in recurrence of malignant disease after blood transfusion (Blajchman 2005). The rates of malignant disease before surgery in the ER and TRAD groups were similar, but mortality due to malignant disease within 2 years post surgery was greater in the TRAD group. As the ER group had a lower postoperative transfusion rate (Malviya et al. 2011), this may have been a factor in the observed rate of deaths due to malignancy in our study. The proportion of deaths related to the more commonly encountered post-surgical complications such as stroke, myocardial infarction, cardiac failure, pneumonia, respiratory failure, pulmonary embolism, and renal failure was greater in the TRAD group. This is the first observational study to specifically assess medium-term mortality in a large number of patients before and after the implementation of an ER program for hip and knee arthroplasty. We found a survival benefit in the longer term following implementation of the ER program. The cause of this survival benefit is still not known, but the present study further supports the routine use of ER programs for hip and knee replacement.
  12 in total

1.  Readmissions after fast-track hip and knee arthroplasty.

Authors:  Henrik Husted; Kristian Stahl Otte; Billy B Kristensen; Thue Orsnes; Henrik Kehlet
Journal:  Arch Orthop Trauma Surg       Date:  2010-06-10       Impact factor: 3.067

Review 2.  The logrank test.

Authors:  J Martin Bland; Douglas G Altman
Journal:  BMJ       Date:  2004-05-01

Review 3.  Transfusion immunomodulation or TRIM: what does it mean clinically?

Authors:  M A Blajchman
Journal:  Hematology       Date:  2005       Impact factor: 2.269

Review 4.  Evidence-based surgical care and the evolution of fast-track surgery.

Authors:  Henrik Kehlet; Douglas W Wilmore
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

5.  An enhanced recovery programme for primary total knee arthroplasty in the United Kingdom--follow up at one year.

Authors:  D A McDonald; R Siegmeth; A H Deakin; A W G Kinninmonth; N B Scott
Journal:  Knee       Date:  2011-08-30       Impact factor: 2.199

6.  Efficacy of an accelerated recovery protocol for Oxford unicompartmental knee arthroplasty--a randomised controlled trial.

Authors:  K A Reilly; D J Beard; K L Barker; C A F Dodd; A J Price; D W Murray
Journal:  Knee       Date:  2005-10       Impact factor: 2.199

7.  Determinants of long-term survival after major surgery and the adverse effect of postoperative complications.

Authors:  Shukri F Khuri; William G Henderson; Ralph G DePalma; Cecilia Mosca; Nancy A Healey; Dharam J Kumbhani
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 8.  Multimodal strategies to improve surgical outcome.

Authors:  Henrik Kehlet; Douglas W Wilmore
Journal:  Am J Surg       Date:  2002-06       Impact factor: 2.565

9.  Accelerated perioperative care and rehabilitation intervention for hip and knee replacement is effective: a randomized clinical trial involving 87 patients with 3 months of follow-up.

Authors:  Kristian Larsen; Ole Gade Sørensen; Torben B Hansen; Per B Thomsen; Kjeld Søballe
Journal:  Acta Orthop       Date:  2008-04       Impact factor: 3.717

10.  Enhanced recovery program for hip and knee replacement reduces death rate.

Authors:  Ajay Malviya; Kate Martin; Ian Harper; Scott D Muller; Kevin P Emmerson; Paul F Partington; Mike R Reed
Journal:  Acta Orthop       Date:  2011-09-06       Impact factor: 3.717

View more
  30 in total

1.  Adherence to the ERAS protocol is Associated with 5-Year Survival After Colorectal Cancer Surgery: A Retrospective Cohort Study.

Authors:  Ulf O Gustafsson; Henrik Oppelstrup; Anders Thorell; Jonas Nygren; Olle Ljungqvist
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

Review 2.  A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs.

Authors:  Ester Miralpeix; Alpa M Nick; Larissa A Meyer; Juan Cata; Javier Lasala; Gabriel E Mena; Vijaya Gottumukkala; Maria Iniesta-Donate; Gloria Salvo; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2016-03-09       Impact factor: 5.482

3.  Sustainability after structured implementation of ERAS protocols.

Authors:  Olle Ljungqvist
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

4.  Early morbidity after simultaneous and staged bilateral total knee arthroplasty.

Authors:  Martin Lindberg-Larsen; Christoffer C Jørgensen; Henrik Husted; Henrik Kehlet
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-02-07       Impact factor: 4.342

5.  Compliance with the ERAS Protocol and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer.

Authors:  Magdalena Pisarska; Grzegorz Torbicz; Natalia Gajewska; Mateusz Rubinkiewicz; Mateusz Wierdak; Piotr Major; Andrzej Budzyński; Olle Ljungqvist; Michał Pędziwiatr
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

6.  Length of stay and its impact upon functional outcomes following lower limb arthroplasty.

Authors:  Timothy M Brock; Paul N Baker; Steven Rushton; Michelle Bardgett; David Deehan
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-12-30       Impact factor: 4.342

7.  Re-admissions treble the risk of late mortality after primary total hip arthroplasty.

Authors:  Pablo A Slullitel; Martín Estefan; Wilber M Ramírez-Serrudo; Fernando M Comba; Gerardo Zanotti; Francisco Piccaluga; Martín A Buttaro
Journal:  Int Orthop       Date:  2018-03-10       Impact factor: 3.075

8.  Enhanced recovery in lower limb arthroplasty in the Irish setting.

Authors:  J G Galbraith; C Fenelon; J Gibbons; G A Kelly; D Bennett
Journal:  Ir J Med Sci       Date:  2017-02-07       Impact factor: 1.568

Review 9.  Preoperative education for hip or knee replacement.

Authors:  Steve McDonald; Matthew J Page; Katherine Beringer; Jason Wasiak; Andrew Sprowson
Journal:  Cochrane Database Syst Rev       Date:  2014-05-13

10.  Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes.

Authors:  Larissa A Meyer; Javier Lasala; Maria D Iniesta; Alpa M Nick; Mark F Munsell; Qiuling Shi; Xin Shelley Wang; Katherine E Cain; Karen H Lu; Pedro T Ramirez
Journal:  Obstet Gynecol       Date:  2018-08       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.